Emtricitabine — Discount Pricing

Other medications in Infections

• Entecavir
• Ertapenem
• Erythromycin
• Ethambutol
• Famciclovir
• Fluconazole
• Foscarnet
• Fosfomycin

About Emtricitabine

Emtricitabine is a crucial medication often prescribed for the management and prevention of HIV. Understanding its role and how to access it affordably is vital for many individuals. At TheDrugClub, we're committed to helping our members significantly reduce their prescription costs, ensuring you can obtain essential medications like emtricitabine without unnecessary financial strain.

Emtricitabine is an important antiretroviral medication used in the fight against HIV. For those managing HIV or seeking to prevent its transmission, understanding this drug is key.

What Emtricitabine Treats

Emtricitabine is primarily used for two main purposes: the treatment of HIV-1 infection and pre-exposure prophylaxis (PrEP) to prevent HIV-1 infection. When used for treatment, it's typically part of a combination therapy with other antiretroviral drugs, helping to reduce the viral load in the body and improve immune function. For PrEP, emtricitabine is combined with tenofovir disoproxil fumarate or tenofovir alafenamide to reduce the risk of sexually acquired HIV-1 in at-risk adults and adolescents.

How Emtricitabine Works

Emtricitabine belongs to a class of drugs called nucleoside reverse transcriptase inhibitors (NRTIs). HIV, the virus that causes AIDS, needs an enzyme called reverse transcriptase to multiply and spread within the body. Emtricitabine works by blocking this enzyme, thereby disrupting the virus's ability to replicate. This action helps to keep the viral load low in infected individuals and prevents the virus from establishing itself in those taking it for prevention.

Typical Costs of Emtricitabine

As a specialized medication, emtricitabine, especially when combined with other drugs, can carry a significant price tag. Without insurance or a prescription savings program, the cost can be a substantial barrier for many. Prices can vary widely based on the pharmacy, dosage, and whether a generic or brand-name version is dispensed. These high costs underscore the importance of exploring all available options to make your medication more affordable.

How TheDrugClub Helps Members Save

At TheDrugClub, we understand the financial burden prescription medications can impose. We work to

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Emtricitabine is approved for (FDA label)

Emtricitabine is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. Emtricitabine, a nucleoside analog HIV-1 reverse transcriptase inhibitor, is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. ( 1 )

Source: Read the full FDA label on DailyMed. Label effective date: August 18, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Emtricitabine (FDA label)

WARNING: POSTTREATMENT ACUTE EXACERBATION OF HEPATITIS B Severe acute exacerbations of hepatitis B (HBV) have been reported in patients who are coinfected with HIV-1 and HBV and have discontinued e mtricitabine. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who are coinfected with HIV-1 and HBV and discontinue emtricitabine. If appropriate, initiation of anti-hepatitis B therapy may be warranted [see Warnings and Precautions ( 5.1 )] . WARNING: POSTTREATMENT ACUTE EXACERBATION OF HEPATITIS B See full prescribing information for complete boxed warning. Severe acute exacerbations of Hepatitis B (HBV) have been reported in patients coinfected with HIV-1 and HBV who have discontinued Emtricitabine. Hepatic function should be monitored closely in patients coinfected with HIV-1 and HBV who discontinue Emtricitabine. If appropriate, initiation of anti-hepatitis B therapy may be warranted. ( 5.1 )

Source: FDA prescribing information (DailyMed). Set ID: a229c922-58eb-4795-9219-6cebb1779e35. SPL document ID: f4575438-cafb-44c7-b35a-25e87792a85f. Label effective date: August 18, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Emtricitabine (FDA label)

Emtricitabine Capsules, containing 200 mg of emtricitabine, are size '1' capsules with sky blue cap imprinted with "EMT" in black and white body imprinted with "200" in black. Capsules: 200 mg ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: a229c922-58eb-4795-9219-6cebb1779e35. SPL document ID: f4575438-cafb-44c7-b35a-25e87792a85f. Label effective date: August 18, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Emtricitabine (FDA label)

The following adverse reactions are discussed in other sections of the labeling: Severe Acute Exacerbation of Hepatitis B in Patients Coinfected with HIV-1 and HBV [see Warnings and Precautions ( 5.1 )] . Immune Reconstitution Syndrome [see Warnings and Precautions ( 5.2 )] Lactic Acidosis/Severe Hepatomegaly with Steatosis [see Warnings and Precautions ( 5.3 )] . Most common adverse reactions (incidence ≥10%) are headache, diarrhea, nausea, fatigue, dizziness, depression, insomnia, abnormal dreams, rash, abdominal pain, asthenia, increased cough, and rhinitis.

Source: FDA prescribing information (DailyMed). Set ID: a229c922-58eb-4795-9219-6cebb1779e35. SPL document ID: f4575438-cafb-44c7-b35a-25e87792a85f. Label effective date: August 18, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Emtricitabine (FDA label)

Emtricitabine is contraindicated in patients with previously demonstrated hypersensitivity to any of the components of the products. Emtricitabine is contraindicated in patients with previously demonstrated hypersensitivity to any of the components of the products. ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: a229c922-58eb-4795-9219-6cebb1779e35. SPL document ID: f4575438-cafb-44c7-b35a-25e87792a85f. Label effective date: August 18, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Emtricitabine (FDA label)

Immune reconstitution syndrome: May necessitate further evaluation and treatment. ( 5.2 ) Lactic acidosis/severe hepatomegaly with steatosis: Discontinue treatment in patients who develop symptoms or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity. ( 5.3 ) 5.1 Severe Acute Exacerbation of Hepatitis B in Patients Coinfected with HIV-1 and HBV All patients should be tested for the presence of chronic Hepatitis B virus (HBV) before or when initiating emtricitabine [see Dosage and Administration ( 2.1 )]. Severe acute exacerbations of hepatitis B (e.g., liver decompensation and liver failure) have been reported in patients who are coinfected with HIV-1 and HBV and have discontinued emtricitabine. Patients who are coinfected with HIV-1 and HBV who discontinue emtricitabine should be closely monitored with both clinical and laboratory follow-up for at least several months after stopping treatment.

Source: FDA prescribing information (DailyMed). Set ID: a229c922-58eb-4795-9219-6cebb1779e35. SPL document ID: f4575438-cafb-44c7-b35a-25e87792a85f. Label effective date: August 18, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Emtricitabine (FDA label)

The potential for drug interactions with emtricitabine has been studied in combination with AZT, indinavir, d4T, famciclovir, and tenofovir DF (TDF). There were no clinically significant drug interactions for any of these drugs. Drug interactions trials are described elsewhere in the labeling [see Clinical Pharmacology ( 12.3 )].

Source: FDA prescribing information (DailyMed). Set ID: a229c922-58eb-4795-9219-6cebb1779e35. SPL document ID: f4575438-cafb-44c7-b35a-25e87792a85f. Label effective date: August 18, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.